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Background: Retrospective analyses in the West suggest that mutations in KRAS codons 61 and 146, BRAF, NRAS,
and PIK3CA are negative predictive factors for cetuximab treatment in colorectal cancer patients. We developed a
novel multiplex kit detecting 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA using Luminex
(xMAP) assay in a single reaction.
Methods: Tumor samples and clinical data from Asian colorectal cancer patients treated with cetuximab were collected.
We investigated KRAS, BRAF, NRAS, and PIK3CA mutations using both the multiplex kit and direct sequencing methods,
and evaluated the concordance between the 2 methods. Objective response, progression-free survival (PFS), and overall
survival (OS) were also evaluated according to mutational status.
Results: In total, 82 of 83 samples (78 surgically resected specimens and 5 biopsy specimens) were analyzed using both
methods. All multiplex assays were performed using 50 ng of template DNA. The concordance rate between the
methods was 100%. Overall, 49 (59.8%) patients had all wild-type tumors, 21 (25.6%) had tumors harboring KRAS codon
12 or 13 mutations, and 12 (14.6%) had tumors harboring KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA
mutations. The response rates in these patient groups were 38.8%, 4.8%, and 0%, respectively. Median PFS in these
groups was 6.1 months (95% confidence interval (CI): 3.1–9.2), 2.7 months (1.2–4.2), and 1.6 months (1.5–1.7); median OS
was 13.8 months (9.2–18.4), 8.2 months (5.7–10.7), and 6.3 months (1.3–11.3), respectively. Statistically significant
differences in both PFS and OS were found between patients with all wild-type tumors and those with KRAS codon 61,
KRAS codon 146, BRAF, NRAS, or PIK3CA mutations (PFS: 95% CI, 0.11–0.44; P < 0.0001; OS: 95% CI, 0.15–0.61; P < 0.0001).
Conclusions: Our newly developed multiplex kit is practical and feasible for investigation of a range of sample types.
Moreover, mutations in KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA detected in Asian patients were not
predictive of clinical benefits from cetuximab treatment, similar to the result obtained in European studies.
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reproduction in any medium, provided the orand Japan have recommended compulsory KRAS muta-
tion testing before treatment [1-6]. Although conven-
tional KRAS tests are useful to decrease treatment to
nonbeneficiary populations, the efficacy of determining
beneficiary populations requires improvement. The re-
sponse rate to anti-EGFR antibody monotherapy among
pretreated patients with tumors harboring KRAS codons
12 and 13 wild-type is 13%–17% [1,2], and that of combin-
ation anti-EGFR antibody and cytotoxic agent therapy is
11%–35% [5,7]. One explanation for such relatively low ef-
ficacy is that molecular alterations other than KRAS codonLtd. This is an Open Access article distributed under the terms of the Creative
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antibody therapies. Recent retrospective studies have re-
vealed that mutations in KRAS codons 61 and 146, BRAF,
NRAS, and PIK3CA are also related to resistance to anti-
EGFR antibodies [8-13].
Several issues should also be considered to establish the
clinical utility of expanded genome biomarker tests for
anti-EGFR antibodies. First, information about the relation
between mutation status and efficacy of treatment, espe-
cially among Asian populations, is still limited. Second, ef-
ficacious quality-controlled in vitro diagnostic kits and
systems suitable for multiple genome biomarker detection
are needed.
In Japan, a KRAS mutation assay kit based on the
ARMS–scorpion method that detects seven frequently ob-
served mutations in KRAS codons 12 and 13 (TheraScreen®
K-RAS Mutation Kit; QIAGEN) was first approved for
in vitro diagnostic use, and a kit using Luminex (xMAP)
assay (MEBGEN KRAS Mutation Detection Kit, MBL)
followed [14,15]. We recently developed another Luminex-
based research-use kit, GENOSEARCH Mu-PACK, which
simultaneously detects 36 mutations in KRAS codons 61
and 146, BRAF, NRAS, and PIK3CA. In addition to the
hitherto approved KRAS codon 12 and 13 mutation kit,
the multiplex kit identifies mutations by a single tube reac-
tion using 50 ng of template DNA from formalin-fixed
paraffin-embedded (FFPE) specimens.
In this study, we examined the feasibility and robustness
of this multiplex kit using routine clinical samples collected
from multiple hospitals. Meanwhile, we collected precise
clinical data for these cases and retrospectively analyzed
the relation of the mutation profiles of expanded markers
to clinical outcomes following cetuximab therapy.
Methods
Patients
We screened and selected clinical and pathological data
from consecutive patients who were administered either
cetuximab monotherapy or cetuximab plus irinotecan be-
tween July 2008 and April 2010.
Patients who met all of the following inclusion cri-
teria were retrospectively included in the analyses:
(1) age ≥20 years; (2) histologically confirmed adenocarcin-
oma of the colon or rectum; (3) presence of unresectable
metastatic disease; (4) baseline computed tomography (CT)
performed within 28 days of initial cetuximab administra-
tion; (5) initial CT evaluation performed within 3 months
of initial cetuximab administration; (6) previously docu-
mented as refractory or intolerant to fluoropyrimidines,
oxaliplatin, and irinotecan; (7) Eastern Cooperative Oncol-
ogy Group performance status score ≤2; and (8) adequate
hematological, hepatic, and renal functions.
In the monotherapy regimen, cetuximab was adminis-
tered at an initial dose of 400 mg/m2 followed by weeklyinfusions of 250 mg/m2. In the cetuximab plus irinotecan
regimen, cetuximab was administered at the same dose as
for monotherapy and followed by biweekly infusions of
150 mg/m2 irinotecan, as per the manufacturer’s instruc-
tions for irinotecan in Japan.
The study was conducted with the approval of the Na-
tional Cancer Center Institutional Review Board, Cancer
Institute Hospital of Japanese Foundation for Cancer Re-
search Review Board, National Hospital Organization
Shikoku Cancer Center Review Board, Shizuoka Cancer
Center Review Board, Saitama Cancer Center Review
Board, Hokkaido University Review Board, and the Ethics
Committee of the University of Toyama. Written in-
formed consent was obtained from as much patients who
were alive as possible. For the deceased patients and their
relatives, we also disclosed the study design at the web-
site of National Cancer Center and gave them chances to
express their wills in accordance with Epidemiological
Study Guideline of Ministry of Health, Labour and Welfare
in Japan.
Tissue samples and DNA extraction
Genomic DNA was obtained from primary and meta-
static colorectal cancer tissues of all patients treated with
cetuximab. Tissue samples harvested by biopsy or surgi-
cal resection at the participating hospitals were collected
and sent to the research institution (MBL, Japan). A 2-μm
hematoxylin-eosin (HE) slide and a 10-μm unstained slide
were obtained from the FFPE tissue blocks; the latter was
subsequently sliced into 3–10 sections. Pathological diag-
noses were confirmed by a pathologist (Satoshi Fujii), with
reference to the 4th edition of the WHO classification. The
tumor area, determined by examining HE slides, was
macroscopically dissected. Genomic DNA was isolated as
described previously [16].
Luminex (xMAP) tests
A total of 36 mutations of KRAS codon 61 (Q61K, Q61E,
Q61L, Q61P, Q61R, Q61H), KRAS codon 146 (A146T,
A146S, A146P, A146E, A146V, A146G), BRAF codon 600
(V600E), NRAS codon 12 (G12S, G12C, G12R, G12D,
G12V, G12A), codon 13 (G13S, G13C, G13R, G13D,
G13V, G13A), codon 61 (Q61K, Q61E, Q61L, Q61P, Q61R,
Q61H), PIK3CA exon 9 codon 542 (E542K), codon 545
(E545K), codon 546 (E546K), and exon 20 codon 1047
(H1047R, H1047L) were analyzed using Luminex (xMAP)
technology (GENOSEARCH Mu-PACK, MBL, Japan).
First, 50 ng of template DNA collected from FFPE tis-
sue samples was amplified by polymerase chain reaction
(PCR) using a biotin-labeled primer. Thereafter, the PCR
products and fluorescent Luminex beads (oligonucleotide
probes complementary to wild and mutant genes were
bound to the beads) were hybridized and labeled with
streptavidin–phycoerythrin. Subsequently, the products
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analyzed using UniMAG software (MBL, Japan). The pro-
cedure time was approximately 4.5 h.
We also used the Luminex assay kit (MEBGEN KRAS
Mutation Detection Kit, MBL, Japan) currently approved
for clinical use by the Ministry of Health, Labour and
Welfare of Japan [16] to detect KRAS codon 12 and 13
mutations.
Direct sequencing methods
In addition, to confirm the mutations detected by the
Luminex assays, the same mutations of KRAS codons 61
and 146, BRAF, NRAS, and PIK3CA were analyzed by
direct sequencing. A total of 700 ng of template DNA
was used for these PCR reactions and the PCR products
were directly sequenced with the same primers used for
PCR. A BigDye Terminator v3.1 Cycle Sequencing Kit and
an ABI PRISM 3730xl DNA Analyzer (Life Technologies)
were used. Analyses of DNA sequences were performed
using Sequencher (GeneCodes).
Statistical analysis
Response rates (RRs) and disease control rates (DCRs)
(including complete or partial response and stable disease)
were evaluated as per the Response Evaluation Criteria
in Solid Tumors (RECIST) (version 1.0). Progression-
free survival (PFS) was defined as the time from initial
administration of a cetuximab-containing regimen to ei-
ther the first objective evidence of disease progression
or death from any cause. Overall survival (OS) was defined
as the time from initial administration of a cetuximab-
containing regimen to death from any cause. RRs, DCRs,
PFS, and OS of all patients were re-evaluated by the prin-
cipal investigators at each institution. The relative dose
intensity was defined as the ratio of the actual dose ad-
ministered to the planned dose.
Fisher’s exact test and the Kruskal–Wallis test were
used to compare patient characteristics, relative dose in-
tensity, and treatment response. PFS and OS data were
plotted as Kaplan–Meier curves, and differences among
the groups according to KRAS, BRAF, NRAS, and PIK3CA
gene status were compared using the log-rank test and
hazard ratio calculated from a Cox regression model with a
single covariate. All analyses were performed by a biostatis-
tician (Takeharu Yamanaka), using IBM SPSS® Statistics 21
package software (SPSS Inc., Tokyo, Japan).Table 1 Template DNA harvested from FFPE specimens
Surgicall
Number of specimens 78
Total amount of template DNA (ng) [median (range)] 25,114 (2
Amount of template DNA per slice (ng) [median (range)] 8,371 (91Results
Concordance between Luminex and direct sequencing
From September 2008 to April 2010, 376 patients were
treated with a cetuximab-containing regimen at seven
institutions. Of these, 83 patients met the inclusion
criteria and specimens were collected from them for
analysis (232 patients did not meet the inclusion cri-
teria and 61 specimens could not be collected). We
collected 78 surgically resected specimens and 5 bi-
opsy specimens, from which the median amount of
template DNA collected was 25,114 ng (range: 2740–
84,738) and 1691 ng (range:1469–2668), respectively
(Table 1).
One patient’s gene status could not be detected by either
Luminex or direct sequencing because DNA harvested
from the resected metastatic liver specimens could not be
amplified by PCR. In the remaining 82 patients, the con-
cordance rate for mutations between the 2 methods was
100% (Table 2).
Among the 82 specimens, 3 KRAS codon 61 mutations
(3.6%), 2 KRAS codon 146 mutations (2.4%), 4 BRAF mu-
tations (4.9%), 2 NRAS mutations (2.4%), and 4 PIK3CA
mutations (4.9%) (1 in exon 9 and 3 in exon 20) were
detected using both the expanded kit and direct sequen-
cing. Moreover, we identified 15 KRAS codon 12 mutations
(18.3%) and 6 KRAS codon 13 mutations (7.3%); in total,
21 samples (25.6%) with KRAS codon 12 or 13 mutations
were detected by using the KRAS Luminex assay kit. All
mutations except for PIK3CA were mutually exclusive
(Table 2, Figure 1).
Patient characteristics
Clinical data were collected from 83 patients. We used
data from 82 patients whose genomic DNA could be
successfully examined using both the expanded kit and
direct sequencing. Six of the 82 patients were treated
with cetuximab monotherapy, while the remaining 76 were
treated with a regimen of cetuximab plus irinotecan.
Of these 82 patients, 49 had tumors with no mutation
(all wild type), 21 had tumors with mutation of either
KRAS codon 12 or 13, and 12 had tumors with mu-
tation of either KRAS codon 61, KRAS codon 146, BRAF,
NRAS, or PIK3CA. No significant difference was observed
in the characteristics of these three groups except for the
ratio of refractoriness to intolerance of prior oxaliplatin
(Table 3).y resected Biopsy Total
5 83
,740–84,738) 1,691 (1,469–2,668) 22,591 (1,469–84,738)
4–28,246) 370 (154–889) 7,530 (154–28,246)









KRAS codon 61 3 3 100% 3.6%
Q61K 0 0 100% 0%
Q61E 0 0 100% 0%
Q61L 0 0 100% 0%
Q61P 0 0 100% 0%
Q61R 0 0 100% 0%
Q61H 3 3 100% 3.6%
KRAS codon 146 2 2 100% 2.4%
A146T 2 2 100% 2.4%
A146S 0 0 100% 0%
A146P 0 0 100% 0%
A146E 0 0 100% 0%
A146V 0 0 100% 0%
A146G 0 0 100% 0%
BRAF codon 600 4 4 100% 4.9%
V600E 4 4 100% 4.9%
NRAS codon 12 2 2 100% 2.4%
G12S 0 0 100% 0%
G12C 0 0 100% 0%
G12R 0 0 100% 0%
G12D 2 2 100% 2.4%
G12V 0 0 100% 0%
G12A 0 0 100% 0%
NRAS codon 13 0 0 100% 0%
G13S 0 0 100% 0%
G13C 0 0 100% 0%
G13R 0 0 100% 0%
G13D 0 0 100% 0%
G13V 0 0 100% 0%
G13A 0 0 100% 0%
NRAS codon 61 0 0 100% 0%
Q61K 0 0 100% 0%
Q61E 0 0 100% 0%
Q61L 0 0 100% 0%
Q61P 0 0 100% 0%
Q61R 0 0 100% 0%
Q61H 0 0 100% 0%
PIK3CA Exon 9 1 1 100% 1.2%
E542K 1 1 100% 1.2%
E545K 0 0 100% 0%
E546K 0 0 100% 0%
Table 2 Concordance between Luminex and direct
sequencing (Continued)
PIK3CA Exon 20 3 3 100% 3.7%
H1047R 1 1 100% 1.2%
H1047L 2 2 100% 2.4%
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RRs of patients with all wild-type tumors (N = 49), KRAS
codon 12 or 13 mutations (N = 21), and mutations of
KRAS codon 61, KRAS codon 146, BRAF, NRAS, or
PIK3CA (N = 12) were 38.8%, 4.8%, and 0%, respectively
(Table 4). Partial response was observed in one patient
with a KRAS codon G12C mutation. In addition, DCRs
were 77.6%, 57.1%, and 33.3%, respectively, for these pa-
tient groups (Table 4). Differences for both RRs and
DCRs between patients with all wild-type tumors and
those with KRAS codon 61, KRAS codon 146, BRAF,
NRAS, or PIK3CA mutations were statistically significant
(Fisher’s exact test, RRs: P = 0.006, DCRs: P = 0.006). On
the other hand, there were no statistically significant differ-
ences between patients with KRAS codon 12 or 13 muta-
tions and those with KRAS codon 61, KRAS codon 146,
BRAF, NRAS, or PIK3CA mutations (Fisher’s exact test,
RRs: P = 0.636, DCRs: P = 0.170).
The relative dose intensity of cetuximab was signifi-
cantly higher among patients with KRAS codon 61,
KRAS codon 146, BRAF, NRAS, or PIK3CA mutations.
However, the number of treatment cycles was signifi-
cantly greater among patients with all wild-type tumors
(Table 4).
RR for all patients included in the study was 24.4%,
whereas that for patients with KRAS codon 12 or 13 wild-
type tumors was 31.1%. Furthermore, RR for patients with
all wild-type tumors was 38.8%.Figure 1 Associations among KRAS, BRAF, NRAS, and PIK3CA
mutations. KRAS codon 12 and 13, KRAS codon 61 and 146,
BRAF, and NRAS mutations were mutually exclusive. Only PIK3CA
Exon 9 and 20 mutations overlapped KRAS codon 12 and 13 and
BRAF mutations.
Table 3 Baseline patient characteristics
All wild-type KRAS codon 12,
13 mutations
KRAS codon 61, codon 146, BRAF, NRAS
or PIK3CAmutations (any other mutations)
(N = 49) (N = 21) (N = 12)
Treatment
Cetuximab + irinotecan (%) 47 (96) 19 (90) 10 (83) P = 0.212†
Cetuximab monotherapy (%) 2 (4) 2 (10) 2 (17)
Age
Median (range) 61 (29–78) 65 (51–80) 65 (43–76) P = 0.605‡
Gender
Male (%) 31 (63) 16 (76) 6 (50) P = 0.312†
Female (%) 18 (37) 5 (24) 6 (50)
ECOG PS
0 (%) 34 (69) 13 (62) 5 (42) P = 0.185†
1–2 (%) 15 (31) 8 (38) 7 (58)
Primary lesion
Colon (%) 28 (57) 15 (71) 9 (75) P = 0.416†
Rectum (%) 21 (43) 6 (29) 3 (25)
Site of Metastasis
Liver
Yes (%) 33 (67) 13 (62) 8 (67) P = 0.945†
No (%) 16 (33) 8 (38) 3 (33)
Lung
Yes (%) 34 (69) 15 (71) 9 (75) P = 1.000†
No (%) 15 (31) 6 (29) 3 (25)
Lymph node
Yes (%) 26 (53) 7 (33) 9 (75) P = 0.068†
No (%) 23 (47) 14 (67) 3 (25)
Peritoneum
Yes (%) 11 (22) 3 (14) 2 (17) P = 0.791†
No (%) 38 (78) 18 (86) 9 (83)
No. of metastatic sites
1 (%) 9 (18) 9 (42) 3 (25) P = 0.106†
>2 (%) 40 (82) 12 (58) 9 (75)
Prior chemotherapy
Fluoropyrimidine
Refractory (%) 49 (100) 21 (100) 12 (100)
Intolerant (%) 0 (0) 0 (0) 0 (0)
Oxaliplatin
Refractory (%) 40 (82) 10 (48) 9 (75) P = 0.017†
Intolerant (%) 9 (18) 11 (52) 3 (25)
Irinotecan P = 1.000†
Refractory (%) 48 (98) 21 (100) 12 (100)
Intolerant (%) 1 (2) 0 (0) 0 (0) P = 0.669†
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Table 3 Baseline patient characteristics (Continued)
Before bevacizumab therapy 25 (51) 9 (43) 7 (58)
Yes (%) 24 (49) 12 (57) 5 (42) P = 0.236†
No (%) 12 5 25
Response rate for prior irinotecan-containing
therapies (%)
Pathological classification
G1, G2 (%) 42 (86) 20 (95) 11 (92) P = 0.481†
G3, G4 (%) 7 (14) 1 (5) 1 (8)
ECOG PS Eastern Cooperative Oncology Group performance status.
†: Fisher’s exact test.
‡: Kruskal–Wallis test.
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The median PFS among patients with all wild-type tu-
mors (N = 49), KRAS codon 12 or 13 mutations (N = 21),
and KRAS codon 61, KRAS codon 146, BRAF, NRAS,
or PIK3CA mutations (N = 12) was 6.1 months (95%
confidence interval (CI) 3.1–9.2), 2.7 months (1.2–4.2), and
1.6 months (1.5–1.7), respectively (Table 4, Figure 2A).
Median OS was 13.8 months (9.2–18.4), 8.2 months (5.7–
10.7), and 6.3 months (1.3–11.3), respectively (Table 4,
Figure 2B).
We observed statistically significant differences in both
PFS and OS between patients with all wild-type tumors
and those with KRAS codon 61, KRAS codon 146, BRAF,Table 4 Efficacy in the test population determined on the bas
All wild-type
(N = 49)
KRAS codon 12, 13
mutations (N = 21)
Complete response 1 0
Partial response 18 1
Stable disease 19 11
Progressive disease 11 9
Total 49 21
Response rate (%) 38.8 4.8
Disease control rate (%) 77.6 57.1
Progression-free survival
[Median (95% CI) (months)]
6.1 (3.1, 9.2) 2.7 (1.2, 4.2)
Overall survival [Median
(95% CI) (months)]
13.8 (9.2, 18.4) 8.2 (5.7, 10.7)
Relative dose intensity
Irinotecan [Median (range) (%)] 72.8 (13.0–100) 81.0 (38.4–100)
Cetuximab [Median (range) (%)] 86.0 (35.7–100) 86.3 (11.1–100)
Number of treatment cycles
[Median (range)]
12 (1–86) 5 (1–23)
*: Fisher’s exact test.
**: log rank test.
***: Kruskal–Wallis test.NRAS, or PIK3CA mutations [PFS: hazard ratio (HR),
0.22; 95% CI, 0.11–0.44; P < 0.0001] (OS: HR, 0.30; 95% CI,
0.15–0.61; P < 0.0001) (Figure 2A and 2B). Differences in
PFS and OS between patients with wild-type mutations
and the 8 patients with KRAS codon 61, KRAS codon 146,
NRAS, or PIK3CA mutations were statistically signifi-
cant (PFS: P = 0.001, OS: P = 0.001), but this was not the
case for the 4 patients with BRAF mutations. The median
PFS and OS for these 4 patients were 0.9 months and
11.4 months, respectively.
On the other hand, there were no statistically signifi-
cant differences between patients with KRAS codon 12
or 13 mutations and those with KRAS codon 61, KRASis of gene status
KRAS codon 61, codon 146, BRAF,
NRAS or PIK3CAmutations






0 P = 0.006* (All wild-type vs.
Any other mutations)
33.3 P = 0.006* (All wild-type vs.
Any other mutations)
1.6 (1.5, 1.7) P < 0.0001** (All wild-type vs.
Any other mutations)
6.3 (1.3, 11.3) P < 0.0001** (All wild-type vs.
Any other mutations)
98.0 (49.3–100) P = 0.108***
100 (80.0–100) P = 0.042***
3 (1–12) P < 0.0001***
Figure 2 Kaplan–Meier plots of progression-free survival (PFS) and overall survival (OS) according to KRAS, BRAF, NRAS, and PIK3CA
gene status. Figure 2A. PFS: Median PFS values were 6.1 months [95% confidence interval (CI): 3.1–9.2], 2.7 months (1.2–4.2), and 1.6
months (1.5–1.7) among patients with all wild-type tumors (N = 49, blue line), KRAS codon 12 or 13 mutant tumors (N = 21, green line),
and KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutant tumors (N = 12, gray-line), respectively. Differences in PFS values
between patients with all wild-type tumors and those with KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutant tumors were
statistically significant (hazard ratio, 0.22; 95% CI, 0.11–0.44; P < 0.0001). Figure 2B. OS: Median OS values were 13.8 months [95%
confidence interval (CI): 9.2–18.4], 8.2 months (5.7–10.7), and 6.3 months (1.3–11.3) among patients with all wild-type tumors (N = 49, blue
line), with KRAS codon 12 or 13 mutant tumors (N = 21, green line), and with KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutations
(N = 12, gray-line), respectively. Differences in OS values between patients with all wild-type tumors and those with KRAS codon 61, KRAS codon
146, BRAF, NRAS, or PIK3CA mutant tumors were statistically significant (hazard ratio, 0.30; 95% CI, 0.15–0.61; P < 0.0001).
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P = 0.091, OS: P = 0.236) (Figure 2A and 2B).
We also analyzed the differences in PFS and OS be-
tween patients with KRAS codon 12 mutations and
those with KRAS codon 13 mutations. Similar to our pre-
vious study in a different population [17], there were no
statistically significant differences between these groups
(median PFS: KRAS codon 12, 2.1 months vs. KRAS codon
13, 3.4 months, P = 0.682; median OS: KRAS codon 12,
6.8 months vs. KRAS codon 13, 9.6 months, P = 0.147).
Discussion
This study is the first to verify the relevance of the muta-
tion status of KRAS codons 61 and 146, BRAF, NRAS,
and PIK3CAto the clinical efficacy of anti-EGFR anti-
body therapy among Asian patients. As reported in a
pooled analysis from a European population, patients with
the aforementioned less-frequent mutations exhibited sta-
tistically significant worse outcomes equivalent to those of
KRAS codon 12 and 13 mutants [8]. Though systemically
analyzed studies have not been reported since the first
European analysis, our results strongly support the use-
fulness of the expanded pretreatment test for anti-EGFR
therapies.Because our aim was to compare the outcomes of KRAS
codon 12 and 13 mutant cases with those characterized by
other mutations, clinical data and FFPE specimens of the
patients treated with cetuximab-containing regimens at
seven Japanese cancer centers from July 2008 to April
2010 were collected. At that time, the Japanese authorities
did not require pretreatment KRAS tests, and patients with
KRAS codon 12 and 13 mutations were eventually treated
with cetuximab. However, the proportion of patients with
KRAS codon 12 or 13 mutant tumors in this study (25.6%)
was slightly lower than that in previous reports of Western
and Asian study populations [18], supposedly because sev-
eral participating institutions had established lab-based
tests and used the data for selecting nonbeneficiary popula-
tions. Among KRAS codon 12 and 13 wild-type cases, the
proportion with mutations of overall tested genes (12/61,
19.7%) was similar to that of previous reports, suggesting
that such expanded testing would be equally useful in
Western and Asian countries.
Because the potential usefulness of multiplex mutation
analyses is demonstrated, the development of robust
in vitro diagnostic systems is needed for clinical applica-
tion. The application of multiplex mutation detection sys-
tems in colorectal cancer specimens has been reported.
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using a SNaPshot® Multiplex kit (Life Technologies), which
detects 22 mutations in KRAS, BRAF, NRAS, and PIK3CA
[19]. Here we evaluated a quality-controlled kit detecting
36 mutations of KRAS codons 61 and 146, BRAF, NRAS,
and PIK3CA using Luminex (xMAP) technology. Data
obtained by this kit were fully concordant with those by
conventional direct sequencing, regardless of any vari-
ation in fixation methods between participating institutes
(unpublished data).
This kit has several advantages with regard to its de-
velopment for routine clinical use. It is manufactured
under the same quality as the hitherto approved in vitro
diagnostic kit detecting mutations in KRAS codons 12
and 13. Design of the hands-on operations is simple and
easy; detection of the 36 mutations is performed in a
single reaction of multiplex PCR followed by Luminex
bead assay, with an overall hands-on time of 4.5 h. In
addition, the requirement for template DNA is as low as
50 ng. We collected a median of 370 ng (range: 154–
889) DNA per 10-μm biopsy slice in this study, which is
sufficiently large to perform the test and to reserve
backup DNA. Meanwhile, the ARMS–Scorpion assay,
another approved in vitro diagnostic kit, requires larger
amounts of template DNA. The currently approved
KRAS codons 12 and 13 kit consists of 8 (1 control and 7
mutations) PCR reactions. A total of 80–160 ng of tem-
plate DNA (10–20 ng for each PCR reaction) are needed
to examine a sample [20], and it would be difficult to ex-
pand the PCR reactions because of the limitation of tem-
plate DNA.
It has been estimated that approximately 10%–20% of
all patients with colorectal cancer have either KRAS
codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA
gene mutations, suggesting that approximately 60,000–
120,000 patients (10%–20% of the 600,000 who die
annually from colorectal cancer) worldwide could be
screened by this expanded mutation test. Furthermore,
because the usefulness of regular administration of as-
pirin for patients with mutated PIK3CA colorectal cancer
and the possibility of combining EGFR and BRAF inhibi-
tors for patients with mutated BRAF colorectal cancer
have been reported, detection of those mutations could
become of greater importance in many ways [21,22].
Once further studies with larger sample sizes and a range
of clinical samples provide evidence of its clinical utility,
this technique might advance the precision of colorectal
cancer treatment.
Conclusions
Our newly developed multiplex kit is practical and feasible
for investigating various types of FFPE samples. Moreover,
mutations in KRAS codon 61, KRAS codon 146, BRAF,
NRAS, or PIK3CA detected in Asian patients were notpredictive of clinical benefits from cetuximab treatment,
similar to the result obtained in European studies.
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